Citations

Clear

3030 citation(s) found for "Susan, M".

Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine
Webster, W. Scott, Thompson, R. Houston, Harris, Kimberley J., Frigola, Xavier, Kuntz, Susan M., Inman, Brant A. , Dong, Haidong , Inman, Brant A , Dong, Haidong

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 179 | Issue: 5 | Pages: 2860-2869

10.4049/jimmunol.179.5.2860 | PMID 17709500 Get It

Abstract Development of effective vaccination approaches to treat established tumors represents a focus of intensive research because such approaches offer the promise of enhancing immune system priming against tumor Ags via restimulation of pre-existing (memory) antitumoral helper and effector immune cells. However, inhibitory mechanisms, which function to limit the recall responses of tumor-specific immunity, remain poorly understood and interfere with therapies anticipated to induce protective immunity. The mouse renal cell carcinoma (RENCA) tumor model was used to investigate variables affecting vaccination outcomes. We demonstrate that although a whole cell irradiated tumor cell vaccine can trigger a functional antitumor memory response in the bone marrows of mice with established tumors, these responses do not culminate in the regression of established tumors. In addition, a CD103+ regulatory T (Treg) cell subset accumulates within the draining lymph nodes of tumor-bearing mice. We also show that B7-H1 (CD274, PD-L1), a negative costimulatory ligand, and CD4+ Treg cells collaborate to impair the recall responses of tumor-specific memory T cells. Specifically, mice bearing large established RENCA tumors were treated with tumor cell vaccination in combination with B7-H1 blockade and CD4+ T cell depletion (triple therapy treatment) and monitored for tumor growth and survival. Triple treatment therapy induced complete regression of large established RENCA tumors and raised long-lasting protective immunity. These results have implications for developing clinical antitumoral vaccination regimens in the setting in which tumors express elevated levels of B7-H1 in the presence of abundant Treg cells.
Questionable Relevance of γδ T Lymphocytes in Renal Cell Carcinoma
Inman, Brant A. , Frigola, Xavier, Harris, Kimberley J., Kuntz, Susan M., Lohse, Christine M. , Leibovich, Bradley C. , Kwon, Eugene D., Inman, Brant A

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 180 | Issue: 5 | Pages: 3578-3584

10.4049/jimmunol.180.5.3578 | PMID 18292585 Get It

Abstract Adoptive γδ T cell immunotherapy has moved briskly into clinical trials prompted by several small studies suggesting abundant accumulation of γδ T cells within renal cell carcinoma (RCC). In this study, we re-examined levels of γδ T cells within RCC tumors and correlated levels of these cells with pathologic features and outcome associated with this form of cancer. Tissues from 248 consecutive clear cell RCC tumors obtained from 2000 to 2003 were stained and quantified for total CD3+ and γδ T cells per mm2. Wilcoxon rank sum and Kruskal-Wallis tests were used to evaluate associations between T cell amounts and prognostic factors (age, gender, tumor size, stage, grade, tumor necrosis). Cox models were used to assess associations with RCC-specific death. Median numbers of total CD3+ and γδ T cells were 281/mm2 (interquartile range (IQR): 149–536) and 2.6/mm2 (IQR: 1.3–4.6), respectively. The median percentage of CD3+ T cells that were γδ T cells was 1.0% (IQR: 0.4–1.9). This low percentage of intratumoral γδ T cells was diluted even further with rising CD3+ T cell infiltration. Percentages of γδ T cells were not associated with even one single clinicopathologic feature examined. Median follow-up for this study was 3.1 years (48 patients died of RCC) and Cox analysis failed to demonstrate that γδ T cells (hazard ratio = 1.02, p = 0.25) were predictive of RCC-specific death. γδ T cells are rare and not recruited nor expanded within RCC tumors. Percentages of γδ T cells fail to correlate with any prognostic features of RCC nor specific death. As such, the role of γδ T cells in RCC immunobiology remains questionable.
Eosinophil Deficiency Compromises Parasite Survival in Chronic Nematode Infection
Beiting, Daniel P. , Bliss, Susan K., Gebreselassie, Nebiat , Gagliardo, Lucille F., Lee, Nancy A., Lee, James J. , Appleton, Judith A., Fabre, Valeria

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 182 | Issue: 3 | Pages: 1577-1583

10.4049/jimmunol.182.3.1577 | PMID 19155506 Get It

Abstract Immune responses elicited by parasitic worms share many features with those of chronic allergy. Eosinophils contribute to the inflammation that occurs in both types of disease, and helminths can be damaged or killed by toxic products released by eosinophils in vitro. Such observations inform the widely held view that eosinophils protect the host against parasitic worms. The mouse is a natural host for Trichinella spiralis, a worm that establishes chronic infection in skeletal muscle. We tested the influence of eosinophils on T. spiralis infection in two mouse strains in which the eosinophil lineage is ablated. Eosinophils were prominent in infiltrates surrounding infected muscle cells of wild-type mice; however, in the absence of eosinophils T. spiralis muscle larvae died in large numbers. Parasite death correlated with enhanced IFN-γ and decreased IL-4 production. Larval survival improved when mice were treated with inhibitors of inducible NO synthase, implicating the NO pathway in parasite clearance. Thus, the long-standing paradigm of eosinophil toxicity in nematode infection requires reevaluation, as our results suggest that eosinophils may influence the immune response in a manner that would sustain chronic infection and insure worm survival in the host population. Such a mechanism may be deployed by other parasitic worms that depend upon chronic infection for survival.
Conversion From Sildenafil to Tadalafil
Frantz, Robert P. , Durst, Louise A., Franco, Verónica , McDevitt, Susanne , Walker, Susan , Durst, Louise, Burger, Charles D. , Oudiz, Ronald J. , Bourge, Robert C. , Waxman, Aaron B. , Frantz, Robert P

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | April 18, 2014 | Volume: 19 | Issue: 6 | Pages: 550-557

10.1177/1074248414528066 | PMID 24742768 Get It

Purpose: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil. Methods: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis of recorded adverse events (AEs). Results: Of the 35 patients who met the study criteria, 56% were receiving ≥2 PAH therapies. At the time of transition, the sildenafil dose ranged from 40 to 300 mg/d, with 20% of the patients on >20 mg of sildenafil 3 times daily. Transition to tadalafil was generally well tolerated, and the incidence of common AEs, except for myalgia, appeared to decrease over time on tadalafil therapy. Five (14%) patients switched back to sildenafil. A greater percentage of patients were satisfied than were dissatisfied after conversion to tadalafil (55% vs 19% at 90 days), while 26% felt about the same degree of satisfaction. Conversion to tadalafil resulted in significant improvement in patient ratings of therapy convenience. Conclusions: Transition of patients from sildenafil to tadalafil was usually well tolerated, with improved convenience and may enhance treatment satisfaction.
Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer
Block, Matthew S. , Charbonneau, Bridget, Vierkant, Robert A. , Fogarty, Zachary C. , Bamlet, William R. , Chenevix-Trench, Georgia, AOCS, for, Group, /ACS, Rossing, Mary Anne, Cramer, Daniel, Pearce, Celeste Leigh, Schildkraut, Joellen, Menon, Usha , Kjær, Susanne K. , Levine, Douglas A. , Culver, Hoda Anton, Whittemore, Alice S. , Lambrechts, Diether , Wentzensen, Nicolas , Kupryjańczyk, Jolanta , Chang‐Claude, Jenny , Bandera, Elisa V. , Høgdall, Estrid , Heitz, Florian , Kaye, Stanley B., Fasching, Peter A. , Campbell, Ian , Goodman, Marc T. , Bean, Yukie T., Hays, Laura E., Lurie, Galina, Eccles, Diana , Hein, Alexander , Beckmann, Matthias W. , Ekici, Arif B. , Paul, James, Brown, Robert , Flanagan, James M. , Harter, Philipp , Schwaab, Ira, Høgdall, Claus , Lundvall, Lene, Olson, Sara H. , Orlow, Irene , Paddock, Lisa E. , Eilber, Ursula, Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Ziółkowska-Seta, Izabela, Brinton, Louise A. , García‐Closas, Montserrat , Despierre, Evelyn, Lambrechts, Sandrina, Vergote, Ignace , Walsh, Christine , Lester, Jenny, Sieh, Weiva , McGuire, Valerie , Rothstein, Joseph H. , Ziogas, Argyrios, Lubiński, Jan , Menkiszak, Janusz , Jensen, Allan , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pike, Malcolm C. , Terry, Kathryn L. , Vitonis, Allison F., Ramirez, Starr M., Rider, David N., Knutson, Keith L. , Sellers, Thomas A. , Phelan, Catherine M., Johnatty, Sharon E., DeFazio, Anna , Song, Honglin , Kalli, Kimberly R., Cunningham, Julie M. , Goode, Ellen L. , Chenevix‐Trench, Georgia , Lambrechts, Diether , Pharoah, Paul D.P. , Chenevix-Trench, Georgia, AOCS, for, Group, /ACS, Gronwald, Jacek , Karlan, Beth Y. , Pejovic, Tanja B. , Bois, Andreas du , Rudolph, Anja , Yang, Hannah , Lester, Jenny, Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Berchuck, Andrew , Berg, David Van Den , Knutson, Keith L. , Doherty, Jennifer A. , Tyrer, Jonathan P. , Fridley, Brooke L. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Orlow, Irene , Campbell, Ian G , Bamlet, William R , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Bandera, Elisa V.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 17, 2014 | Volume: 23 | Issue: 7 | Pages: 1421-1427

10.1158/1055-9965.epi-13-0962 | PMID 24740199 Get It

Abstract Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-κB (NF-κB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-κB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10−5). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41–2.35; P = 4.13 × 10−6] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56–0.82; P = 2.33 × 10−5). Other associations of note included TNF receptor–associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77–0.92; P = 6.49 × 10−5) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26–0.73; P = 4.56 × 10−4). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies. Cancer Epidemiol Biomarkers Prev; 23(7); 1421–7. ©2014 AACR.
Allergic Contact Dermatitis of the Vulva
O’Gorman, Susan M., Torgerson, Rochelle R.

Mayo Clinic

Dermatitis® | April 16, 2014 | Volume: 24 | Issue: 2 | Pages: 64-72

10.1097/der.0b013e318284da33 | PMID 23474446 Get It

Background and objectives Allergic contact dermatitis (ACD) of the vulva arises as a primary condition or develops secondary to topical agents. We aimed to describe the incidence of ACD in patients presenting with vulvar symptoms and to identify the allergens of most importance. Patients and Methods Using a database of the patch testing results from 3 geographically distinct sites, we identified patients tested to a gynecologic series between 2003 and 2010. Patients had patch testing to the standard European battery and a gynecologic series. Patch testing was in line with accepted universal methods: application on day 1, allergen removal and initial reading on day 3, and final reading on day 5. Results Ninety patients were included. Thirty-five (39%) had a relevant positive result. The 5 allergens with the highest number of cases with a relevant reaction were natural fragrance mix 2%, balsam of Peru, benzocaine 5%, fragrance mix 8%, and quaternium 15 1%. The most common gynecologic series allergen to cause a relevant reaction was terconazole. Conclusions Allergic contact dermatitis is a frequent finding in patients presenting with vulvar symptoms. We identified a relevant positive result to patch testing in 39%. We found fragrances, medicaments, and preservatives to be of most relevance.
Incidence of chronic lymphocytic leukemia and high‐count monoclonal B‐cell lymphocytosis using the 2008 guidelines
Call, Timothy G. , Hanson, Curtis A. , Achenbach, Sara J., Cerhan, James R. , Rabe, Kari G. , Vachon, Celine M. , Hallberg, Emily J., Norman, Aaron D. , Kay, Neil E. , Zent, Clive S. , Ding, Wei , Vachon, Celine M. , Shanafelt, Tait D. , Slager, Susan L. , Chaffee, Kari G. , Cerhan, James R

Mayo Clinic

Cancer | April 14, 2014 | Volume: 120 | Issue: 13 | Pages: 2000-2005

10.1002/cncr.28690 | PMID 24711224 Get It

BACKGROUNDThe 1996 National Cancer Institute Working Group (NCI‐WG 96) guidelines classified disease in individuals who had a B‐cell clone with chronic lymphocytic leukemia (CLL) immunophenotype as CLL if their absolute lymphocyte count was ≥5 × 109/L. The 2008 International Workshop on CLL guidelines (IWCLL 2008) classified disease as CLL if the absolute B‐cell count was ≥5 × 109/L or as monoclonal B‐cell lymphocytosis (MBL) if the absolute B‐cell count was <5 × 109/L. The objective of the current study of Olmsted County, Minnesota, was to assess the effects of these changes on incidence rates and presentation from 2000 to 2010.METHODSUsing diagnostic indices available through the Rochester Epidemiology Project and the Mayo CLL database, the authors identified all patients with newly diagnosed CLL and high‐count MBL from 2000 to 2010. Age‐specific and sex‐specific incidence rates were determined.RESULTSAccording to NCI‐WG 96 criteria, there were 115 patients with CLL and 8 patients with MBL during the period studied. Using the IWCLL 2008 classification, there were 79 patients with CLL and 40 patients with MBL. Rai stage distribution (low risk, intermediate risk, and high risk) using NCI‐WG 96 criteria was 60.9%, 33.9%, and 5.2%, respectively, compared with 43%, 49.4%, and 7.6%, respectively, using IWCLL 2008 criteria. The age‐adjusted and sex‐adjusted incidence rates (per 100,000) for CLL and MBL were 10.0 and 0.66, respectively, using NCI‐WG 96 criteria versus 6.8 and 3.5, respectively, using IWCLL 2008 criteria. The median time to treatment according to NCI‐WG 96 criteria was 9.2 years versus 6.5 years with IWCLL 2008 criteria.CONCLUSIONSUse of the IWCLL 2008 guidelines reduced the incidence of CLL, altered the distribution of initial Rai stage at diagnosis, and shortened the median time to treatment. Cancer 2014;120:2000–2005. © 2014 American Cancer Society.
Cyclo‐oxygenase‐2 inhibition and endothelium‐dependent vasodilation in youngervs. older healthy adults
Eisenach, John H., Gullixson, Leah R., Allen, Alexander R., Kost, Susan L., Nicholson, Wayne T.

Mayo Clinic

British Journal of Clinical Pharmacology | April 4, 2014 | Volume: 78 | Issue: 4 | Pages: 815-823

10.1111/bcp.12397 | PMID 24698105 Get It

AimA major feature of endothelial dysfunction is reduced endothelium‐dependent vasodilation, which in ageing may be due to decreased production of endothelial prostacyclin, or nitric oxide (NO), or both.MethodWe tested this hypothesis in 12 younger (age 18–38 years, six women) and 12 older healthy adults (age 55–73 years, six post‐menopausal women). Endothelium‐dependent vasodilation was assessed by the forearm vascular conductance (FVC) response to intra‐arterial acetylcholine (ACh) (0.5, 1.0, 2.0, 4.0 μg dl−1forearm tissue min−1) before and 90 min after inhibition of the enzyme cyclo‐oxygenase‐2 (COX‐2) with oral celecoxib (400 mg), followed by the addition of endothelialNOsynthase inhibition with intra‐arterialNG‐monomethyl‐l arginine acetate (L‐NMMA).ResultsAgeing was associated with a significantly reducedFVCresponse toACh(P= 0.009, age‐by‐dose interaction; highest doseFVC±SEMin ageing: 11.2 ± 1.4vs.younger: 17.7 ± 2.4 units,P= 0.02). Celecoxib did not reduce restingFVCor the responses toAChin any group.L‐NMMAsignificantly reduced restingFVCand the responses toAChin all groups, and absoluteFVCvalues followingL‐NMMAwere similar between groups.ConclusionIn healthy normotensive younger and older adults, there is minimal contribution of prostacyclin toACh‐mediated vasodilation, yet theNOcomponent of vasodilation is reduced with ageing. In the clinical context, these findings suggest that acute administration of medications that inhibit prostacyclin (i.e.COX‐2 inhibitors) evoke modest vascular consequences in healthy persons. Additional studies are necessary to test whether chronic use ofCOX‐2 medications reduces endothelium dependent vasodilation in older persons with or without cardiovascular risk factors.
Ia Diastolic Dysfunction: An Echocardiographic Grade
Pandit, Anil , Mookadam, Farouk , Hakim, Fayaz A., Mulroy, Eoin , Saadiq, Rayya A. , Doherty, Mairéad, Cha, Stephen, Seward, James B., Wilansky, Susan

Mayo Clinic

Echocardiography | April 4, 2014 | Volume: 32 | Issue: 1 | Pages: 56-63

10.1111/echo.12600 | PMID 24698472 Get It

ObjectiveTo demonstrate that a distinct group of patients with Grade Ia diastolic dysfunction who do not conform to present ASE/ESE diastolic grading exists.Method and ResultsEchocardiographic and demographic data of the Grade Ia diastolic dysfunction were extracted and compared with that of Grades I and II in 515 patients. The mean of age of the cohort was 75 ± 9 years and body mass index did not differ significantly between the 3 groups (P = 0.45). Measurements of left atrial volume index (28.58 ± 7 mL/m2 in I, 33 ± 10 mL/m2 in Ia, and 39 ± 12 mL/m2 in II P < 0.001), isovolumic relaxation time (IVRT) (100 ± 17 msec in I, 103 ± 21 msec in Ia, and 79 ± 15 msec in II P < 0.001), deceleration time (248 ± 52 msec in I, 263 ± 58 msec in Ia, and 217 ± 57 msec in II P < 0.001), medial E/e′ (10 ± 3 in I, 18 ± 5.00 in Ia, and 22 ± 8 in II), and lateral E/e′ (8 ± 3 in I, 15 ± 6 in Ia, and 18 ± 9 in II P < 0.001) were significantly different in grade Ia compared with I and II. These findings remained significant even after adjusting for age, gender, diabetes, and smoking.ConclusionPatients with echocardiographic characteristics of relaxation abnormality (E/A ratio of <0.8) and elevated filling pressures (septal E/e′ ≥15, lateral E/e′ ≥12, average E/e′ ≥13) should be graded as a separate Grade Ia group.
A159: The Autoimmune Genetic Architecture of Childhood Onset Rheumatoid Arthritis
Marion, Miranda C. , Sudman, Marc , Pichavant, Mina, Ponder, Lori, Reed, Ann M. , Wallace, Carol A., Becker, Mara L. , Rosenberg, Alan , Punaro, Marilynn, Mellins, Elizabeth , Nelson, J. Lee , Rygg, Marite , Cutler, David J. , Bohnsack, John F. , Thompson, Susan D. , Langefeld, Carl D. , Prahalad, Sampath , Cobb, Joanna E. , Hinks, Anne , Yeung, Rae S. M. , Videm, Vibeke , Nordal, Ellen Berit , Brown, Matthew A. , Thomson, Wendy

Mayo Clinic

Arthritis & Rheumatology | March 27, 2014 | Volume: 66 | Issue: S3 | Pages: No page available

10.1002/art.38585 Get It

Background/Purpose:Genome‐wide association studies have identified susceptibility loci for many autoimmune diseases, including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). About 5% of children with JIA have rheumatoid factor positive arthritis that is phenotypically similar to adult seropositive RA, thus representing childhood onset RA (CORA). To understand the genetic architecture of CORA risk relative to other autoimmune diseases, we genotyped CORA cases and controls on the Immunochip, a custom array designed by the Immunochip Consortium to fine map autoimmune disease‐associated loci shared across 11 autoimmune phenotypes.Methods:Genotyping was completed on 340 CORA cases (mean onset age: 10.2 ± 4.2 yrs) and 11624 controls. Standard SNP and sample QC was performed (e.g., removing samples with call rate <98%, admixture outliers). To test for SNP association with CORA a logistic regression model was computed with Caucasian admixture proportions (ADMIXTURE) as covariates (SNPLash). False discovery rate (FDR) adjusted p‐values (PFDR) are reported to account for the actual number of tests computed.Results:SNP rs3129769, near HLA DRB1 was the most significantly associated (PFDR <3×10‐25), and is in linkage disequilibrium with the HLA DRB1 SNP reported in RA (rs660895, PFDR <1×10‐24). Outside the HLA region, 28 regions had ≥1 SNP meeting genome‐wide significance (PFDR<0.05). The best signal of association was on 22q13 (rs9610687, OR = 0.57, PFDR < 0.0002) near IL2RB, followed by the PTPN22 locus (rs6679677, OR = 1.83, PFDR < 0.0005), an intergenic SNP on chromosome 4 (rs970036, OR = 1.78, PFDR < 0.002) and an intronic SNP (19p13, rs3787016 PFDR < 0.002) in the POLR2E gene, which encodes a subunit of RNA polymerase II. Some loci which have previously been implicated in RA had evidence of association including MMEL (rs751358 PFDR < 0.003), IRF5 (rs4731531 PFDR < 0.006) and CCR6 (rs11575078 PFDR < 0.03). In addition using the FDR‐based threshold we identified several potential SNPs (rs10918214, 1q23; rs28491312, 14q31) not previously implicated in RA.Conclusion:Immunochip analysis of the largest cohort of CORA investigated to date has confirmed the HLA DRB1 association and identified several other loci associated with CORA. Comparisons among loci associated with CORA and those identified in RA and other forms of JIA are underway and will help delineate the unique genetic factors for CORA susceptibility.